Skip to content

The Prognostic Value of GDF-15 for Chinese Patients with Coronary Artery Diseases Complicated with Impaired Left Ventricle Function

The Prognostic Value of GDF-15 for Chinese Patients with Coronary Artery Diseases Complicated with Impaired Left Ventricle Function

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RRC-17013396
Enrollment
Unknown
Registered
2017-11-15
Start date
2017-11-30
Completion date
Unknown
Last updated
2017-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure with CAD

Interventions

Case series:Nil

Sponsors

PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
21 Years to 87 Years

Inclusion criteria

Inclusion criteria: 1. Aged = 18 years; 2. Diagnosed with CAD clinically; 3. NYHA cardiac functional classification II-IV; 4. Ejection fraction of left ventricle <40% or Ejection fraction of left ventricle =40% with LAE, LVH or Diastolic dysfunction.;Inclusion criteria: 1. Aged = 18 years; 2. Diagnosed with CAD clinically; 3. NYHA cardiac functional classification II-IV; 4. Ejection fraction of left ventricle <40% or Ejection fraction of left ventricle =40% with LAE, LVH or Diastolic dysfunction.

Exclusion criteria

Exclusion criteria: 1. Planned heart Surgery within 6 months; 2. Patients in acute onset phase of CAD or heart failure (HF) or within less than 1 months into stability judged by the researcher; 3. Patients with Atrial Fibrillation; 4. Patients with pulmonary hypertension; 5. Patients with severe obstructive or restrictive pulmonary diseases; 6. Unable or unwilling to present informed consent.;Exclusion criteria: 1. Planned heart Surgery within 6 months; 2. Patients in acute onset phase of CAD or heart failure (HF) or within less than 1 months into stability judged by the researcher; 3. Patients with Atrial Fibrillation; 4. Patients with pulmonary hypertension; 5. Patients with severe obstructive or restrictive pulmonary diseases; 6. Unable or unwilling to present informed consent.

Design outcomes

Primary

MeasureTime frame
Blood GDF-15level;;Blood GDF-15level;

Countries

China

Contacts

Public ContactHe Kunlun;He Kunlun ;

PLA General Hospital;PLA General Hospital

Hekl301@aliyun.com;Hekl301@aliyun.com+86 13911232619;+86 13911232619

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026